Clinical Trial Update: Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib [Phase 2]

View source ↗

Summary

Phase 2 trial update on erlotinib re-challenge in patients with recurrent EGFR-mutant non-small cell lung cancer who previously received adjuvant erlotinib or g…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2015-04-21